Vimta Labs Q1 revenue up 13.7%, EBITDA margin at 36.4%
Steady pharma testing demand and domestic gains offset food testing weakness. Entry into biologics CRD adds a long-term growth lever.
— 2 earlier stories on Vimta Labs Ltd. →What's new
- Total income of ₹1,129M, up 13.7% YoY
- Net profit at ₹210M, EBITDA margin expands to 36.4%
- Company completed a Ukraine regulatory audit and commenced biologics contract R&D services
Why this matters
A 36.4% EBITDA margin in a mixed demand environment signals cost discipline and pricing power in pharma testing. The biologics entry, while nascent, broadens the addressable market beyond small molecules. But food testing headwinds from global uncertainties remain a drag.
What we're watching
- Revenue trajectory from the biologics CRD business over the next 2-3 quarters
- Recovery in the food testing division as global conditions evolve
- Sustainability of EBITDA margins above 35%
The full read
Vimta Labs delivered a solid quarter. ₹1,129M in total income, up 13.7% YoY. EBITDA margin hit 36.4%, one of its highest in recent periods. The pharma testing business drove the show, while the food testing division, though hit by global uncertainties, was rescued by domestic demand. Two operational milestones: a completed Ukraine audit and the commencement of biologics CRD services. They add incremental depth but won't move the needle immediately. The margin strength is the real headline, in a sector where pricing and utilisation matter more than top-line growth. The open question is how long that holds as the biologics ramp-up and food testing recovery play out.
Questions answered
- How did Vimta Labs perform in Q1 FY27?
- Total income rose 13.7% YoY to ₹1,129M, net profit was ₹210M, and EBITDA margin came in at 36.4%. The pharma testing business saw healthy traction, while food testing faced global uncertainties.
- What drove the strong EBITDA margin?
- The 36.4% margin reflects a favourable mix toward higher-margin pharma testing services and cost control. Management did not itemise specific cost cuts, but the result implies strong operational leverage.
- Is the food testing business in trouble?
- Not entirely. Global uncertainties did impact the division, but domestic gains helped offset the weakness. The segment is still contributing but remains a drag relative to pharma.
- What is the significance of the biologics CRD services launch?
- It marks Vimta's entry into the faster-growing biologics segment, expanding its service line beyond traditional pharmaceutical testing. Revenue from this is early-stage but could add a new growth vector over the medium term.
- Did the company provide any guidance?
- No. The press release contained only management commentary on divisional performance and the new service launch, with no forward-looking revenue or margin guidance.
Vimta Labs Ltd.
Latest quarter · Dec 2024
Strength & growth
Story so far
All notes on VIMTALABS →- 20 Jul 2026 · 3:29 PM IST Vimta Labs Q1 revenue up 13.7%, EBITDA margin at 36.4%
- 2d ago Vimta Labs lands first biologics order, budgets ₹80 cr capex for FY27
- 2d ago Vimta Labs Q1: Revenue up 12%, PAT up 11% — steady but not a catalyst